Researchers have developed a high-tech method to rid the body of infections — even those caused by unknown pathogens. A device inspired by the spleen can quickly clean blood of everything from Escherichia coli to Ebola, researchers report on 14 September in Nature Medicine.
You might want to google the headlines for the entire article.
Good Seeking Alpha article on INCY was posted yesterday. . "Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93, Gilead Most Likely Suitor"
It sounds like the FED is going to change the wording in the policy statements concerning rate hikes which will #$%$ the markets. I'm looking for this to occur in October. I'm hedged with my positions so I wouldn't mind seeing a 10% correction.
Not sure what you mean by "Are you holding something"?
Management sounded like they were caught off guard when the analyst tried to get some sales guidance for Otrexup. The analyst stated the company had previously indicated they could give some forward projections around this timeframe. We got the same thing about trends looking positive but they didn't want to give any numbers & they were looking forward to competition.
Its starting to sound like the street is more interested in the epi-pen then anything else.
Schiro, have you asked management how long or what obstacle's are preventing a company from becoming an approved supplier of neostigmine? Do they anticipate another company seeking approval?
Medac is developing a new auto-injector. I'm unsure if it can be used to administer viscous fluids but do you really think ATRS is the only one that could do so?. You can find some info on it since one of their employees was accused of stealing trade secrets.
I think Tev-tropin 10mg has already been approved. The problem is long-acting competition has taken over the marketplace.
The National Institute for Health and Care Excellence has published new recommendations rejecting the use of Celgene’s Abraxane (nab-paclitaxel) on the National Health Service to treat patients with advanced pancreatic cancer.
NICE says that data provided by Celgene show that the chemo regimen FOLFIRINOX, a first-line option for patients with the disease, was actually more clinically effective than the Abraxane/gemcitabine combination. And while Abraxane/gemcitabine was more effective than gemcitabine alone, it resulted in more serious side effects.
CELG needs PEG.
He gave an example of what happened with glycopyrrolate once a company became the sole supplier. Glycopyrrolate is another anesthesia drug which is used in combination with neostigmine. The pricing went from .60 a vial to $8.
The US Federal Trade Commission (FTC) said Monday that it filed a lawsuit in federal district court accusing several pharmaceutical companies with illegally blocking access to generic versions of the testosterone-replacement therapy AndroGel. Specifically, the FTC alleges that AbbVie and its partner Besins Healthcare filed "baseless" patent infringement claims against potential generic drugmakers aimed at delaying the introduction of generic AndroGel, and "while the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva to further delay generic drug competition."
The stock will go up when unapproved neostigmine is no longer available. My hospital was just restocked with Westward neostigmine which may be a sign that the stock of APP has run out in the US.